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A B S T R A C T
Background
It is common clinical practice to follow patients with colorectal cancer (CRC) for several years following their definitive surgery and/
or adjuvant therapy. Despite this widespread practice there is considerable controversy about how often patients should be seen, what
tests should be performed and whether these varying strategies have any significant impact on patient outcomes.
Objectives
To review the available evidence concerning the benefits of intensive follow up of colorectal cancer patients with respect to survival.
Secondary endpoints include time to diagnosis of recurrence, quality of life and the harms and costs of surveillance and investigations.
Search methods
Relevant trials were identified by electronic searches of MEDLINE, EMBASE, CINAHL, CANCERLIT, Cochrane Controlled Trials
Register, Science Citation Index, conference proceedings, trial registers, reference lists and contact with experts in the field.
Selection criteria
Only randomised controlled trials comparing different follow-up strategies for patients with non-metastatic CRC treated with curative
intent were included.
Data collection and analysis
Trial eligibility and methodological quality were assessed independently by the three authors.
Main results
Eight studies were included in this update of the review. There was evidence that an overall survival benefit at five years exists for patients
undergoing more intensive follow up OR was 0.73 (95% CI 0.59 to 0.91); and RD -0.06 (95% CI -0.11 to -0.02). The absolute
number of recurrences was similar; OR was 0.91 (95% CI 0.75 to 1.10); and RD -0.02 (95% CI -0.06 to 0.02) and although the
weighted mean difference for the time to recurrence was significantly reduced by -6.75 (95% CI -11.06 to -2.44) there was significant
heterogeneity between the studies. Analyses demonstrated a mortality benefit for performing more tests versus fewer tests OR was
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0.64 (95% CI 0.49 to 0.85), and RD -0.09 (95%CI -0.14 to -0.03) and liver imaging versus no liver imaging OR was 0.64 (95%
CI 0.49 to 0.85), and RD -0.09 (95%CI -0.14 to -0.03). There were significantly more curative surgical procedures attempted in the
intensively followed arm: OR 2.41(95% CI 1.63 to 3.54), RD 0.06 (95%CI 0.04 to 0.09). No useful data on quality of life, harms or
cost-effectiveness were available for further analysis.
Authors’ conclusions
The results of our review suggest that there is an overall survival benefit for intensifying the follow up of patients after curative surgery
for colorectal cancer. Because of the wide variation in the follow-up programmes used in the included studies it is not possible to
infer from the data the best combination and frequency of clinic (or family practice) visits, blood tests, endoscopic procedures and
radiological investigations to maximise the outcomes for these patients. Nor is it possible to estimate the potential harms or costs of
intensifying follow up for these patients in order to adopt a cost-effective approach in this clinical area. Large clinical trials underway
or about to commence are likely to contribute valuable further information to clarify these areas of clinical uncertainty.
P L A I N L A N G U A G E S U M M A R Y
Follow-up strategies for patients treated for non-metastatic colorectal cancer
For patients with colorectal cancer treated with curative intent, intensive follow up is associated with improved all-cause survival.
However, from the randomised trials completed and reported to date, it is not clear what constitutes the optimal follow-up regimen.
There is little information available about the harms and costs associated with follow up in this setting.
Ongoing and proposed trials will address issues of quality of life, harms and costs, and clarify the optimum follow-up programme.
Consumer needs and concerns with respect to the value of follow up require further research.
B A C K G R O U N D
Colorectal cancer (CRC) is a commonly diagnosed malignancy
affecting about one person in 20 in most Westernised countries
(DeVita 1997). Approximately two-thirds of patients will present
with potentially curable disease (by surgery +/- adjuvant thera-
pies). Of these 30-40% will relapse with metastatic disease (Rao
1981; Bohm 1993). Surgeons, oncologists and other health pro-
fessionals working in the field of CRC have pursued a number
of strategies to try and improve clinical outcomes. These have in-
cluded population screening, better diagnostic testing, improved
surgical and anaesthetic techniques and more widespread utilisa-
tion of adjuvant therapies.
After definitive treatment is completed, clinician attention turns
to follow-up strategies designed to detect tumour recurrence at
a stage when further curative procedures can be used. Follow-
up strategies have also been developed in order to detect curable
metachronous (i.e. occurring at different times) tumours. There
is overlap between these two strategies; this current review will
focus on the former issue of strategies designed to detect curable
recurrences of the original cancer. These include recurrences which
are localised in either lung, liver, abdomen or pelvis and can be
completely resected or ablated with curative intent.
Following patients after definitive treatment for cancer has be-
come a traditional component of medical care (Edelman 1997). It
is likely that clinicians follow patients after curative treatment for
CRC at least in part to provide positive feedback on their manage-
ment but also to assess the toxicities of treatment and to provide
more accurate outcome data (Audisio 1996). Patients and their
clinicians develop relationships during treatment and follow up
that can make it hard to discharge patients and return responsi-
bility for care back to their primary physician in the community
(Audisio 2000).
A practising clinician can accumulate a large number of follow-up
patients and the surveillance of this cohort consumes significant
resources. The opportunity cost of the resources involved is con-
siderable, limiting the care that the clinician can provide for other
individuals. Few clinicians restrict CRC follow-up visits to clinical
examination only and the temptation to order routine investiga-
tions is often reinforced by patients who desire tests to “prove”
that their disease is under control (Kievit 2000; Audisio 2000).
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Clinicians justify this approach by claiming that recurrences are
being detected earlier than would otherwise occur and that patient
outcomes are improved as a result (Kievit 2000).
Whether systematic follow up can alter long-term clinical out-
comes for CRC remains controversial (Pfister 2004). Whilst
some commentators have concluded that follow up is worthwhile
(Gerdes 1990), others have questioned its effectiveness (Kievit
2000; McArdle 2000). The variation in follow-up programmes
used by clinicians is considerable (Collopy 1992; Connor 2001;
Vernava 1994; Virgo 1995). Routine follow up has the potential
to create psychological harm for patients and any such disadvan-
tages need to be outweighed by improved clinical outcomes (such
as overall survival) that matter to patients. Data from follow-up
studies in other cancers (e.g. breast cancer and overall survival) is
not encouraging in this regard (Rojas 2001).
Follow-up programmes in colorectal cancer should be based on the
anatomic and temporal patterns of tumour recurrence (Audisio
2000; Edelman 1997). The most important phase of follow up is
the first two to three years after primary tumour resection as during
this time the majority of recurrences will become apparent (Bohm
1993; Ovaska 1989). The liver is the most common site of metas-
tases from colorectal cancer. A small proportion (five percent) of
these patients will have liver metastases that are distributed within
the liver in such a fashion that makes them amenable to surgical
resection or ablation (Fleischer 1989). Published series of patients
undergoing such surgical interventions (with significant numbers
of long-term survivors) encourage this approach (Steele 1991). A
number of strategies have been proposed to detect liver metastases
at an early stage in order to identify such patients; these include
monitoring of blood tests (liver function, serum carcinoembry-
onic antigen [CEA]) and routine imaging of the liver ( Fleischer
1989; Sugarbaker 1987).
The psychological outcomes of following patients with cancer
can be positive or negative. Positive outcomes include reassurance
and support. The negative outcomes include false reassurance, in-
creased anxiety, fear associated with early detection of an incur-
able recurrence, morbidity and mortality associated with proce-
dures performed as a result of abnormal results, and distress caused
by false-positive results. Appropriate quality of life measurements
could capture many of these outcomes.
We conducted a systematic review of randomised controlled tri-
als exploring questions relating to the effectiveness of follow-up
strategies in CRC patients treated with curative intent.
O B J E C T I V E S
To review the available evidence concerning the benefits of inten-
sive follow up of colorectal cancer patients with respect to overall
survival.
Secondary endpoints include time to diagnosis of recurrence, qual-
ity of life and the harms and costs of surveillance and investiga-
tions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised-controlled trials comparing different follow-up
strategies for patients with CRC. These included comparisons of
follow up versus no follow up, follow-up strategies of varying in-
tensity and follow up in different healthcare settings (e.g. primary
care versus hospital).
Types of participants
Males and females of any age with histologically proven adeno-
carcinoma of colon or rectum, staged as T1,2,3,4; N0,1,2; M0
(Dukes’ stage A, B, and C) (Fleming 1997) treated surgically with
curative intent (+/- adjuvant treatment).
Types of interventions
Follow-up visits with health professionals including symptom en-
quiry, clinical examination, procedures (e.g. colonoscopy), blood
tests, faecal analysis and radiological examinations.
Types of outcome measures
Primary: Overall survival
Secondary: disease specific survival, time to diagnosis of recur-
rence, incidence of surgery (with curative intent) for recurrence,
interval (between planned visits) recurrences, quality of life, harms
and costs of surveillance and investigations.
Search methods for identification of studies
See: Collaborative Review Group search strategy
All randomised-controlled trials on this subject were searched
electronically (over the time period indicated) using MEDLINE
(1966-March2006), EMBASE (1980-March2006), Cochrane
database (2006, Issue 1), CINAHL (1982-March2006), Science
Citation Index (1990-March2006) and the Cochrane Colorectal
Cancer Group trial register (compiled fromhand searching. Refer-
ence lists of published articles were searched and personal contact
made with experts. Non-English and unpublished studies were
identified.
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SEARCH STRATEGIES FOR COLORECTAL CANCER RE-
CURRENCE/FOLLOW-UP
MEDLINE
1 exp colorectal neoplasms/ (41439)
2 randomized controlled trial.pt. (117650)
3 randomization/ (19868)
4 randomized controlled trials/ (33435)
5 double blind method/ (40763)
6 single blind method/ (7165)
7 random$.af. (265554)
8 or/2-7 (271495)
9 recur:.ti,ab,sh. (135747)
10 recurrence/ (47820)
11 neoplasm recurrence, local/ (23209)
12 neoplasm metastasis/ (13991)
13 or/9-12 (154189)
14 follow up studies/ (147980)
15 follow-up.ti,ab,sh. (177354)
16 exp longitudinal studies/ (271672)
17 exp survival analysis/ (55781)
18 exp mortality/ (98719)
19 exp prognosis/ (325173)
20 office visits/ (2151)
21 episode of care/ (730)
22 exp population surveillance/ (17642)
23 Physician’s Practice Patterns/ (14482)
24 exp treatment outcome/ (222713)
25 exp “outcome assessment (health care)”/ (240958)
26 exp quality of life/ or quality of life.mp. (54636)
27 or/14-26 (724852)
28 1 and 8 and 13 (791)
29 1 and 8 and 27 (1682)
30 28 or 29 (1887)
31 limit 30 to human (1858)
32 limit 31 to yr=2004-2006 (496)
33 controlled clinical trials/ (2732)
34 controlled clinical trial.pt. (25172)
35 33 or 34 (27878)
36 1 and 13 and 27 and 35 (39)
37 limit 36 to human (39)
38 limit 37 to yr=2004-2006 (4)
39 32 or 38 (500)
EMBASE
1 colon tumor/ (1313)
2 colon cancer/ (9853)
3 colon adenocarcinoma/ (2408)
4 colon carcinoma/ (4764)
5 colorectal carcinoma/ (5457)
6 colorectal tumor/ (1209)
7 sigmoid carcinoma/ (247)
8 rectum cancer/ (3471)
9 rectum tumor/ (551)
10 rectum carcinoma/ (2294)
11 rectum adenoma/ (578)
12 colorectal cancer/ (18180)
13 or/1-12 (45934)
14 randomization/ (16482)
15 randomized controlled trial/ (90686)
16 double blind procedure/ (40318)
17 single blind procedure/ (4871)
18 random$.af. (222067)
19 or/14-18 (228204)
20 metastasis/ (34269)
21 cancer recurrence/ (27864)
22 tumor recurrence/ (5848)
23 recurrent disease/ (30146)
24 (recur$ or metastas:).ti,ab. (157915)
25 or/20-24 (189305)
26 13 and 19 and 25 (1013)
27 (rat or rats or mouse or mice).ti,ab,sh. (610531)
28 (monkey$ or rabbit$ or hamster$).ti,ab,sh. (79914)
29 (bovine or sheep).ti,ab,sh. (48905)
30 animal/ or experimental animal/ (2994)
31 or/27-30 (712536)
32 26 not 31 (949)
33 longitudinal study/ (10546)
34 (follow-up or follow up).ti,ab. (191648)
35 follow up/ (151107)
36 prospective study/ (46568)
37 treatment outcome/ (238867)
38 cancer survival/ (60773)
39 quality of life/ (55014)
40 prognosis/ (100024)
41 mortality/ (88414)
42 morbidity/ (45881)
43 exp survival/ (127648)
44 or/33-43 (688917)
45 13 and 19 and 44 (1622)
46 45 not 31 (1582)
47 46 not 32 (831)
48 case report/ (394297)
49 letter/ or letter.pt. (196163)
50 48 or 49 (548260)
51 32 or 47 (1780)
52 51 not 50 (1751)
53 limit 52 to yr=2004-2006 (518)
CINAHL
1 exp colonic neoplasms/ (1096)
2 exp rectal neoplasms/ (293)
3 exp colorectal neoplasms/ (3257)
4 or/1-3 (3257)
5 follow-up studies/ or follow up.tw. (57969)
6 follow up.mp. (20367)
7 recurrence/ or neoplasm recurrence/ (5583)
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8 recur$.ti,ab,sh. (10254)
9 longitudinal.mp. (6831)
10 or/5-9 (68666)
11 4 and 10 (517)
12 meta analysis/ (4559)
13 (meta analy$ or metaanaly$).mp. (5406)
14 cochrane$.ti,ab. (3765)
15 nursing interventions.pt. (527)
16 literature review/ or literature searching/ (2500)
17 computerized literature searching/ (2977)
18 reference databases/ (653)
19 (review$ or overview$).ti,ab. (70579)
20 (pooled data or pooled analy$).ti,ab. (272)
21 review.pt. (43484)
22 (systematic$ or methodologic$ or quantitative$ or research$
or literature or studies or trial$ or effectiv$).ti,ab. (203796)
23 21 and 22 (19455)
24 (synthes$ adj3 (leterature$ or research$ or studies or
data)).ti,ab. (1374)
25 ((data adj2 pool$) and studies).ti,ab. (191)
26 ((hand or manual$ or database$ or computer$) adj2
search$).ti,ab. (1751)
27 ((electronic$ or bibliograph$) adj2 (database$ or data
base$)).ti,ab. (843)
28 or/12-20 (77127)
29 or/23-27 (22415)
30 28 or 29 (85792)
31 11 and 30 (90)
32 random$.af. (76611)
33 11 and 32 (117)
34 31 or 33 (180)
35 (letter or case study).pt. (92744)
36 34 not 35 (176)
CANCERLIT and Healthstar
These databases are now subsumed by PubMed.
Current Contents, Science Citation Index
As these databases do not have index terms a combination of the
following key words were used: (colorectal or colon* or rectum or
rectal) cancer, recur*; follow-up; longitudinal or prospective; ran-
dom*; double blind; single blind; outcome; survival; morbidity;
mortality;
PubMed was searched and limited to the last 60 days to identify
very recent publications.
Cochrane Library, DARE, HTA.
A simple strategy using: Colorectal neoplasms or rectal neoplasms
or colonic neoplasms) AND (follow* or recur*) was used.
Retrieval was for any language and for the full range of years cov-
ered by the databases.
Data collection and analysis
Three authors checked the titles and abstracts identified from the
databases. The authors obtained the full text of all studies of pos-
sible relevance for independent assessment. The authors decided
which trials met the inclusion criteria and graded their method-
ological quality. Any disagreement was resolved by discussion be-
tween the authors. Authors of primary studies were contacted for
clarification where necessary.
Data extractionwas independently performed by the three authors
and the authors of trials were contacted to provide missing data
where possible. Data was checked and entered into RevMan by an
author. The following data was extracted when available: number
of patients, their age and tumour status, inclusion and exclusion
criteria, setting, treatment regimen, follow-up details and survival,
adverse events and quality of life indices.
A weighted treatment effect (using fixed-effects) was calculated
across trials using the Cochrane statistical package, RevMan ver-
sion 4.2.8. The results were expressed as odds ratios (OR) and
95% confidence intervals (CI) and risk differences (RD with 95%
CI) for dichotomous outcomes (RD reported rather than RR in
response to peer reviewer suggestion) and weighted mean differ-
ences (WMD and 95% CI) for continuous outcomes. All analy-
ses were by intention-to-treat. Time-to-event analyses were con-
ducted (where possible) for time to death (survival). These were
approximated by either analysing for different follow-upperiods or
calculating a weighted average of median survival duration across
studies.
Sub-group analyses were used to investigate possible differences in
patient outcomes according to study variables.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Eight studies met the inclusion criteria (Kjeldsen 1997; Makela
1995; Ohlsson 1995; Pietra 1998; Rodriguez 2006; Schoemaker
1998; Secco 2002; Wattchow 2006). Seven were randomised con-
trolled trials comparing varying levels of follow up after curative
surgery for colorectal cancer and one was a randomised controlled
trial investigating the effect of setting of follow up on outcomes
(Wattchow 2006). The Secco 2002 publication incorporated two
studies within one. Their patients were initially stratified into high
risk or low risk (of recurrence). The high risk patients were then
randomised to intensive follow up or minimal follow up whilst
the low risk patients were randomised to low intensity follow up
or minimal follow up. Four studies recruited patients from a sin-
gle hospital, one included patients from two hospitals (Ohlsson
1995). Rodriguez 2006, Schoemaker 1998 and Wattchow 2006
were multi-centred. In seven trials (Kjeldsen 1997; Makela 1995;
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Ohlsson 1995; Pietra 1998; Rodriguez 2006; Schoemaker 1998;
Secco 2002) follow-up strategies were undertaken at tertiary hos-
pitals. In one trial (Wattchow 2006) the intervention assessed
was follow up in general practice. Overall these studies included
2141 patients with CRC but no evidence of residual cancer af-
ter their primary surgical treatment. Survival at five years af-
ter primary surgical treatment of colorectal cancer was the main
outcome in seven studies (Kjeldsen 1997; Makela 1995; Pietra
1998; Rodriguez 2006; Schoemaker 1998; Secco 2002;Wattchow
2006), one (Ohlsson 1995) examined disease specific survival and
five considered the frequency and time to local recurrence (Makela
1995; Ohlsson 1995 Pietra 1998; Secco 2002; Wattchow 2006).
One study assessed costs (but didn’t publish the data) (Secco 2002)
and Rodriguez 2006 evaluated cost per attempted curative surgery
at recurrence. Two studies assessed quality of life (reported sep-
arately in a second publication - Kjeldsen 1999 and Wattchow
2006). There was considerable variation in the follow-up strate-
gies employed by the eight trials; both the frequency of the follow-
up visits, and the investigations that were performed at each visit
were different in each study (see characteristics of included stud-
ies). One trial (Ohlsson 1995) compared the effect of hospital-
based follow up with no formal follow up and one trial assessed
the intervention of setting for follow up (Wattchow 2006).
Risk of bias in included studies
Themethodological quality of the included trials was documented
with respect to the following criteria: adequacy of randomisation,
concealment of randomisation, baseline comparison of experi-
mental groups, blinding, explicit diagnostic criteria, completeness
of follow up, intention-to-treat analysis, absence of confounding
co-interventions, adequate inclusion and exclusion criteria, and
careful definition and timing of outcomemeasures. The trials were
ranked using the Cochrane approach as to whether they met the
necessary quality criteria: grade A, clearly yes; grade B, not sure;
grade C, clearly no. Where there was uncertainty authors of pri-
mary studies were contacted for clarification. The agreement on
methodological assessment between the authors was reported.
Effects of interventions
Methodological quality.
Although all the studies were reported to be randomised only two
studies explicitly reported that the allocation of patients to study
groups was concealed (Makela 1995; Wattchow 2006). Patient or
clinician blinding was not possible. One study used independent
radiologists assessing CT scans who were blinded to study group
allocation (Schoemaker 1998). Seven studies ensured that out-
come data was obtained from more than 80% of participants. For
Wattchow 2006 outcome data was obtained for 77% of partici-
pants. All studies conducted intention-to-treat analyses. Two stud-
ies ( Rodriguez 2006; Schoemaker 1998) examined compliance
with the follow-up regimen but no study fully assessed contam-
ination. A fixed-effect model was used for all the meta-analyses.
Individual patient data could not be obtained. There was com-
plete concordance between authors regarding evaluation of trial
methodology.
Intensive versus minimalist follow up.
A meta-analysis was performed with data from six trials (Kjeldsen
1997;Makela 1995; Ohlsson 1995; Pietra 1998; Rodriguez 2006;
Schoemaker 1998) using all overall survival at five years as the
outcome (data from Secco 2002 could not be included; nor could
Wattchow 2006 as for this trial the intervention was setting). The
odds ratio and risk difference for overall survival associated with
more intensive follow up was OR 0.73 (95% CI 0.59 to 0.91)
and RD -0.06 (95% CI -0.11 to -0.02) respectively, which was
significant. There was no significant heterogeneity. The odds ratio
and risk difference for the number of recurrences as the outcome
was OR 0.91 (95%CI 0.71 to 1.10) and RD -0.02 (95%CI -0.06
to 0.02) respectively, not significant. For disease specific survival,
two studies (Kjeldsen 1997; Ohlsson 1995) were included: OR
was 0.92 (95% CI 0.64 to 1.31), and RD -0.01 (95% CI -0.08 to
0.05 ) which was not significant.
Clinic visits versus no clinic visits.
There was one study related to mortality (Ohlsson 1995) and two
for recurrence (Ohlsson 1995; Secco 2002). For overall survival;
OR was 0.57 (95% CI 0.26 to 1.29), RD -0.12 (95% CI -0.30
to 0.05), which was not significant. For recurrence OR was 0.85
(95% CI 0.58 to 1.25), RD -0.04 (95% CI -0.13 to 0.05) not
significant; there was no significant heterogeneity.
More clinic visits versus fewer clinic visits.
For the two studies (Kjeldsen 1997; Pietra 1998) that examined
more clinic follow-up visits compared to fewer visits for overall
survival, OR was 0.78 (95% CI 0.58 - 1.05) and RD -0.05 (95%
CI -0.12 to 0.01) respectively. For recurrence, OR was 0.93 (95%
CI 0.69 to 1.26) and RD -0.02 (95% CI -0.08 to 0.05) respec-
tively. Neither meta-analysis was associated with any significant
heterogeneity.
More tests versus fewer tests.
Five studies (Makela 1995; Ohlsson 1995; Pietra 1998, Rodriguez
2006; Schoemaker 1998) compared more versus fewer tests in fol-
low up. For overall survival OR was 0.64 (95% CI 0.49 to 0.85)
and RD -0.09 (95% CI -0.14 to -0.03) significantly favouring the
use of more tests. For recurrence OR was 0.90 (95% CI 0.69 to
1.16) and RD -0.02 (95% CI -0.08 to 0.03) were not significant.
Neither meta-analysis was associated with any significant hetero-
geneity.
For one of the planned comparisons (community follow up versus
hospital only follow up) only a single study (Wattchow 2006) was
located and formal meta-analysis was not undertaken.
CEA versus no CEA estimation.
Two studies were included in this analysis (Ohlsson 1995; Secco
2002), useable data for survival was not available for Secco 2002.
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For overall survival OR was 0.57 (95% CI 0.26 to 1.29), and
RD -0.12 (95% CI -0.30 to 0.05) which was not significant. For
recurrence OR was 0.85 (95% CI 0.58 to 1.25), and RD -0.04
(95% CI -0.13 to 0.05) which was not significant. There was no
significant heterogeneity.
Liver imaging versus no liver imaging.
Six studies (Makela 1995; Ohlsson 1995; Pietra 1998; Rodriguez
2006; Schoemaker 1998; Secco 2002) examined the use of liver
imaging (data for survival was not available for Secco 2002). Over-
all survival OR was 0.64 (95% CI 0.49 to 0.85) RD -0.09 (95%
CI -0.14 to -0.03) which was significant. For recurrence OR was
0.88 (95% CI 0.70 to 1.10) RD -0.03 (95% CI -0.08 to 0.02)
which was not significant. Neither meta-analysis was associated
with any significant heterogeneity.
Time to recurrence.
In a meta-analysis involving three studies (Makela 1995; Ohlsson
1995; Pietra 1998), the mean difference for the time to recurrence
was significantly reduced OR -6.75 months (95% CI -11.06 to
-2.44). However there was significant heterogeneity between the
studies. For those patients randomised to follow up in primary care
or secondary care (Wattchow 2006), the mean time to recurrence
in the general practice follow up group was 9.5 months, and 8.0
months for the surgeon follow up group (p=0.76).
Curative surgery for recurrence.
More surgical procedures for recurrences 101/354 (28%)were per-
formed in the experimental arms of the included studies compared
with 44/351(12%) in the control arms of the studies. Curative
surgery for recurrence OR was 2.41 (95% CI 1.64 to 3.54), and
RD 0.06 (95% CI 0.04 to 0.09), which was significant.
Metachronous tumours.
The total numbers of metachronous tumours detected in the ex-
perimental and control groups of the seven studies were 15 and
nine respectively. One study reported interval tumours and noted
eight in the control group and two in the experimental arm (Pietra
1998).
Complications.
A single study (Schoemaker 1998) reported the adverse events
associated with follow up. They reported two perforations and two
gastrointestinal haemorrhages (requiring transfusion) from a total
of 731 colonoscopies.
Quality of Life.
The only information assessing the influence of different follow-
up strategies on quality of life involved the 350 Danish partic-
ipants in the study by Kjeldsen 1997. In a separate publication
(Kjeldsen 1999) they reported a small but significant (p<0.05) in-
crease in quality of life, as measured by the Nottingham Health
Profile, associated with more frequent follow-up visits compared
to virtually no follow up. Wattchow 2006 assessed depression and
anxiety, quality of life and patient satisfaction in a cohort of pa-
tients randomised to follow up of their colon cancer in different
settings (see characteristics of included studies). They found that
the study patients remained in the normal range for depression
and anxiety with no difference between the two groups at either 12
or 24 months. Study patients (in each arm) had reduced physical
quality of life at baseline, which improved as the study progressed,
but there were no significant differences between the two groups.
There were no differences between the two groups on the patient
satisfaction scale and both groups reported high levels of satisfac-
tion with their care.
Costs.
Secco 2002 provided risk adapted follow up based on prognostic
factors prospectively identified, and the authors comment that risk
adapted follow up reduced costs for those with a better progno-
sis. Rodriguez 2006 performed a cost minimisation analysis, and
demonstrated that although the cost of intensive follow up was
higher, when resectability of recurrences was considered, the cost
per resectable tumour recurrence was lower in the intensively fol-
lowed group.
D I S C U S S I O N
The results of our review suggest that there is an overall survival
benefit for intensifying the follow up of patients after curative
surgery for colorectal cancer. The analyses did not show a signifi-
cant difference in the incidence of recurrence between the patients
in the experimental groups and the control groups. However sig-
nificantly more surgical procedures for recurrence were performed
in the experimental arms of the trials. This suggests that recur-
rences in the more intensively followed groups may have been de-
tected earlier allowing for effective salvage treatments leading to
better survival. However this result is susceptible to intervention
bias. The decision to attempt salvage surgery in these studies was
made by clinicians with knowledge (i.e. unblinded) of which study
group the patients were randomised towhich could introduce such
a bias. There is a significant difference in the time to recurrence
between the groups which supports this contention but signifi-
cant heterogeneity exists between these studies making this result
unreliable. A systematic difference in the clinical management of
patients in each of the study groups could produce such a bias.
Although no statistical heterogeneity was observed between the
studies, differences in the study populations (e.g. exclusion of
Dukes A patients in two studies (Pietra 1998; Rodriguez 2006)
and study design may challenge the validity of combining these
results in a meta-analysis. We recognise that with only seven stud-
ies, the statistical tests for heterogeneity have low power. Each fol-
low-up strategy combined a number of different components in-
cluding frequency of visits, type of clinical assessment, types and
frequency of tests and the setting in which follow up was con-
ducted. No trial compared the addition of one specific interven-
tion and the feasibility of comparing strategies with a variety of
components and varying complexity becomes problematic. A spe-
cific variation across the studies was the intensity of follow up.
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For example the follow-up intensity in the experimental group of
the study by Ohlsson 1995 was similar to the intensity of follow
up in the control groups of other studies in the review (Makela
1995; Pietra 1998; Schoemaker 1998). A precise indication of the
optimal combinations of frequency, type and setting for follow-up
investigations for these patients is therefore not possible to extract
from these data.
A further limitation of systematically combining data from these
studies is the long time-frame over which the various studies have
been conducted. The first of the included studies (Kjeldsen 1997)
began recruiting patients in 1983 and the study byRodriguez 2006
enrolled patients up to and including 2001 (see table of included
studies). During that time clinical care and surgical techniques
have evolved considerably, the feasability of surgical metastastec-
tomy (or ablation) has been extended, the resolution of imaging
modalities has improved significantly and new methods of detect-
ing metastases and recurrences (e.g. PET scanning) have been in-
troduced. As a result of more sensitive imaging modalities the rates
of false positive tests will increase which will in turn affect the costs
of surveillance programmes. Systemic adjuvant therapies and ef-
fective palliative chemotherapy drugs are now widely utilised with
significant prolongation of survival rates. All these factors question
the validity of applying the results of early studies to the modern
surgical and oncological setting.
The use of liver imaging seems to be associated with improved
survival. This is supported by the finding that more tests are also
associated with improved survival and this would lend support
to the inclusion of this investigation in any proposed follow-up
programme.
A study by investigators in Adelaide, South Australia (Wattchow
2006) randomised patients with CRC to identical follow-up
schedules in either a hospital setting or in general practice. This
is the only study we are aware of which specifically addresses the
setting of follow up and assesses quality of life. It is reassuring to
find that patients being followed for colon cancer have levels of
anxiety and depression which were in the normal range for the
Australian population. Their initial reduced physical quality of life
improved over the duration of the study (24 months) and patients
reported high levels of patient satisfaction with their follow-up
care. While studies in breast cancer follow up have examined the
effect of different settings for follow up with high levels of sat-
isfaction amongst those women followed by their family doctors
(Grunfeld 1999) there were no significant differences reported by
the patients in the two different follow-up settings in the study by
Wattchow 2006.
The potential harms (physical, psychological) and costs of fol-
low-up strategies have not been well delineated by the RCTs in-
cluded in this review. In the only study that reported harms from
colonoscopy, (Schoemaker 1998) the rate of perforation (2/731
- 0.2%) was consistent with other published series (Araghizadeh
2001; Bowles 2004). None of the study reports included specific
details of any harms (mortality or morbidity) resulting from in-
vestigation or treatment of recurrences. These outcomes should be
available in order to fully assess any net benefit or harm of follow
up.
The psychological effects of follow up have been investigated by
some researchers (Wattchow 2006; Kjeldsen 1999; Stiggelbout
1997). These studies have reported mixed effects on quality of life
measures but no study has found a deterioration in quality of life.
Further research is required into the value that patients place on
follow up after their curative surgery. Any survival benefit (or lack
of benefit) of follow up would have to be considered along with
the views of patients so that follow-up programmes are accessible,
acceptable and address all patients needs and concerns.
Nouseful data is available from the studies in this reviewon the cost
effectiveness of followup in this group of patients.Without a better
understanding of which of the specific follow-up interventions is
responsible for the improvement in outcomes it is not possible
to even speculate on the potential cost effectiveness of any one
approach. Investigators have previously tried to project the costs
of a single intervention such as serum CEA testing (Audisio 1996;
Moertel 1993) and the reported costs have appeared prohibitively
large. In contrast an incremental cost effectiveness analysis based
on five randomised controlled trials has reported costs of intensive
follow up which appear acceptable in the setting of the National
Health Service in the United Kingdom (Renehan 1994) although
the authors do acknowledge a number of limitations of their study.
It is essential that future studies address the issue of costs so that
the relative cost effectiveness of follow up can be viewed from an
economic perspective as well as a clinical one.
The search for RCTs relevant to this review has brought to our
attention a number of studies in progress or completed and as yet
unpublished. Between 1982 and 1993 a Cancer Research Cam-
paign sponsored a clinical trial in the UK exploring the role of
rising serum CEA levels in prompting investigations for recurrent
disease and or second look laparotomy. Serum CEA levels were
measured in all patients and216with rising levelswere randomised
to whether their doctors were informed of the rising CEA level or
not. The results have been presented as an abstract (Lennon 1994)
and discussions with the investigators to allow access to the trial
data are in progress.
The GILDA group of investigators in Italy are currently conduct-
ing a RCT of “intensive” versus “minimalist” follow up in patients
with Dukes B or C CRC which commenced in 1998. Their out-
comes of interest include: overall survival, CRC mortality, quality
of life and time to detection of recurrence. They aimed to enrol
a minimum of 2920 patients and by June 2006 had randomised
1240 patients across 45 centres (Fossati 2006). Although prelim-
inary data have been published (Grossmann 2004) from this on-
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going study the authors of this review have chosen not to include
the data at this stage in view of the short follow up period and
because recruitment is ongoing.
A large RCT commissioned by the NHS in the UK (FACS trial)
has commenced recruiting. The trial aims to randomise 4890 pa-
tients in a two by two factorial design exploring the effect of CEA
monitoring in primary care and intensive hospital follow up with
CT and ultrasound scanning. A protocol amendment in 2005
now allows clinicians to choose (or not) prior to randomisation to
perform a CT scan at 12-18 months regardless of trial group allo-
cation. Outcome measures will include the overall survival at five
years, quality of life of survivors, cost of follow up and cost to the
NHS per life saved. The detection of metastatic disease suitable
for surgical treatment is a key feature of the study and all patients
will be managed by multidisciplinary teams that include access to
liver and lung surgeons (www.facs.soton.ac.uk). By Jan 2006 376
patients had been randomised.
Themulticentre COLOFOL study has been commenced by inves-
tigators in Denmark, Sweden, Poland, UK, and The Netherlands
(COLFOL www.colofol.com). The study began randomising pa-
tients in early 2006 and aims to enroll 2,500 patients. Participants
are randomised to either a “low frequency follow-up regimen” or a
“high frequency follow-up regimen”. All patients will have serum
CEA measured and imaging of the chest and liver but at different
time intervals.
The GILDA study, the FACS study and the COLOFOL study
plan to enrol far greater numbers of patients than previous studies
have attempted. If successfully completed these studies are likely
to produce a more reliable estimate of the effectiveness of follow
up in improving patient outcomes. In addition to assessing quality
of life the GILDA and FACS studies will address cost effectiveness
of the various follow-up programmes. The FACS study has the
added advantage of including an essentially “no follow up” control
group so that the absolute benefit of follow up can be quantified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this review support the general principle of clinical
followup for patientswithCRCafter curative treatment. The exact
details of the optimal follow-up regimen still need clarification.
Implications for research
Clinicians in Europe and the UK are encouraged to enrol their
patients in the three large ongoing trials in this field. These trials
are addressing the deficiencies in research to date with respect to
quality of life and cost effectiveness. These trials are also more
likely to reflect any advances in modern surgical technique and
the use of adjuvant therapies. All investigators are encouraged to
explicitly document any harms relating to follow up and subse-
quent interventions.
Consumer needs and concerns relating to the value of follow up
should to be explored in separate research programmes incorpo-
rating other study designs using qualitative as well as quantitative
methods.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kjeldsen 1997
Methods RCT (random numbers)
Accrual: 1983-1994
dropouts=0
Stratified for Duke’s stage, tumour location
Participants 597 patients, (326 men and 271 women ) treated with primary radical surgery for CRC, no residual
neoplasia.
Inclusion criteria: age less than 76 years, no complicating disease making follow up impossible, no other
major cancer within the past five years, permanent residency within the county of Funen.
Duke’s A 138
Duke’s B 293
Duke’s C 166
Colon primary 314
Rectal primary 283
Interventions Experimental group had follow-up examinations at 6,12,18,30,36,48,60,120,150, & 180 months after
radical surgery.
Control group had examinations at 60,120,180 months.
Examinations included: medical history, clinical examination, digital rectal examination (DRE), gynae-
cological examination, Haemoccult-II test, colonoscopy, CXR, haemoglobin level, erythrocyte sedimen-
tation rate and liver enzymes
Outcomes Local recurrence
Metachronous tumours
Overall survival
Cancer-related survival
Notes Definition of radical surgery: no residual neoplasia detected by following examinations: complete
colonoscopy or incomplete colonoscopy plus double-contrast barium enema, CXR (2 views), histological
evaluation of all surgical margins, biopsy of suspicious lesions (lymph nodes), inspection and palpation
of liver during surgery.
Local recurrence defined as tumour growth in the region of the primary radical operation, including the
surgical wound, and demonstrated clinically or by imaging techniques, but not necessarily verified by
biopsy.
Metachronous tumours when diagnosed at least 12 months after primary cancer.
Setting: Denmark
Accrual dates:1983-1994
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Makela 1995
Methods RCT
Accrual: 1988-1990
dropouts=0
Single centre trial
Participants 106 patients (52 men, 54 women) who had “radical primary surgery for CRC” at the Oulu University
Hospital 1988-1990
Duke’s A 28
Duke’s B 48
Duke’s C 30
Colon primary 75
Rectal primary 31
Interventions All patients reviewed at 3,6,9,12,15,21,24,30,36,42,48,54 and 60 months. At each visit; history, exami-
nation, FBC, faecal occult blood test, CEA, CXR performed.
Experimental group: patients who had rectal or sigmoid tumours had flexible sigmoidoscopy with video
imaging 3 monthly.
Colonoscopy at 3 months (if had not been done pre-op), then annually.
Ultrasound liver and primary site at 6 months, then annually.
Control group: patients who had rectal and sigmoid cancers had rigid sigmoidoscopy , barium enema
annually
Outcomes Local recurrence
Regional recurrence
Time to detection of recurrence
Recurrence rates
Method of detection of recurrence
Mode of recurrence
Resectability
Overall survival
Notes Radical resection: macroscopic removal of tumour, with microscopically negative margins.
Local recurrence: restricted to anastomosis and its surrounds
Regional recurrence: invasion beyond the site of the primary without distant metastases.
Setting: Finland
Accrual dates:1988-1990
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Ohlsson 1995
Methods RCT
Accrual: 1983-1986
dropouts=0
Single center trial
Participants 107 patients (51 men, 56 women) undergoing resection with curative intent for CRC at the departments
of surgery in Lund and Helsingborg, Sweden, from 1983-1986.
Exclusions: local excision only, distant metastases, patients in whom age or severe illness was considered to
preclude treatment of recurrent disease, inability to co-operate, Crohn’s disease, ulcerative colitis, familial
polyposis, incomplete colonoscopy together with uncertain findings at barium enema examination.
Duke’s A 19
Duke’s B 47
Duke’s C 41
Colon primary 71
Rectal primary 36
Interventions The experimental group: were seen at 3,6,9,12,15,18,21,24,30,36, 42,48, and 60 month intervals. Per-
formed at each visit were clinical exam, rigid proctosigmoidoscopy, CEA, alkaline phosphatase, gamma-
glutaryl transferase, faecal haemoglobin, CXR. Examination of anastomosis (flexible sigmoidoscopy or
colonoscopy, as dictated by the lesion), was performed at 9,21,42 months. Colonoscopy was performed
at 3,15,30,60 months. CT pelvis performed at 3,6,12,18,24 months.
Control group: no follow-up visits planned. They received written instructions recommending they leave
faecal samples with the district nurse for examination every third month during the first two years after
surgery then once a year. Instructed to contact the surgical department if they had any symptoms
Outcomes Overall survival
Local recurrence
Anastomotic recurrence
Symptomatic recurrence
Resection with curative attempt
Time to first recurrence
Protocol compliance
Notes Local recurrence: tumour recurrence within the initial tumour bed, operative field, anastomosis or struc-
tures contiguous or adherent to the primary tumour (included relapse in the abdominal wound, drain
site, pelvis or perineum).
Anastomotic recurrence: intraluminal recurrence within 5 cm of the anastomosis.
Symptomatic: when symptoms could be related to the patient’s initial illness, and when they resulted in
or would have resulted in the patient seeking advice.
Resection with curative attempt: all visible tumour removed, microscopic tumour-free margins.
Time to first recurrence: interval between primary surgery and unequivocal demonstration of recurrent
tumour at laparotomy, imaging or autopsy.
Setting: Sweden
Accrual dates:1983-1986
Risk of bias
Item Authors’ judgement Description
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Ohlsson 1995 (Continued)
Allocation concealment? Unclear B - Unclear
Pietra 1998
Methods RCT
Accrual: 1987-1990
Single centre trial dropouts=0
Participants 207 consecutive patients (111 men, 96 women) who had curative resections for large bowel cancer, all
had colonoscopy at 3 months post-op, if had not been done pre-operatively.
Exclusions: Duke’s A, liver metastases, severe concurrent illness precluding follow up or treatment of
recurrent disease.
Duke’s A 0
Duke’s B 122
Duke’s C 85
Colon primary
139
Rectal primary 68
Interventions Experimental group:seen at 3,6,9,12,15,18,21,24,30,36,42,48,54,60 months, then annually thereafter.
Clinical examination, ultrasound, CEA, CXR at each visit. Annual CT liver and colonoscopy were per-
formed.
Control group: seen at 6 and12months, then annually. At each visit, clinical examination,CEA, ultrasound
performed. They had annual CXR, yearly colonoscopy and CT
Outcomes Local recurrence
Intramural recurrence
Overall survival
Notes Local recurrence: all local disease detectable at follow-up, either alone, or in conjunction with generalised
recurrence.
Local recurrences were divided into extramural recurrences, where tumour regrowth was located in and
around the tumour bed, including the pericolic fat, adjoining mesentery, lymph nodes. Intramural recur-
rence: regrowth involving only the anastomosis.
A local recurrence was considered resected when no macroscopic /microscopic disease remained after
surgery.
Setting: Italy
Accrual dates:1987-1990
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
16Follow-up strategies for patients treated for non-metastatic colorectal cancer (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rodriguez 2006
Methods RCT,
Accrual: 1997-2001
multi-centred, stratified for centre, tumour location, stage
Participants 259 patients, stage II and III colon and rectal cancer
Interventions Experimental group seen with history, examination, bloods (including CEA) at 3,6,9,12,15,18,21,24,
27,30,33,36,39,42,45,48,51,54,57,60 months. US/CT at 6,12,18,24,30,36,42,48,56 months, CXR and
colonoscopy at 12,24,36,48,56 months.
Conrtol group seen with history, examination, bloods (including CEA) 3,6,9,12,15,18,21,24,27,30,33,
36,39,42,45,48,51,54,57,60 months
Outcomes Local recurrence, curative re-operation rates, overall survival
Notes Setting:Spain
Accrual dates:1997-2001
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Schoemaker 1998
Methods RCT
random number tables.
Accrual: 1984-1990
Dropouts=18
2 centres in trial
Experimental =10
Control =8
Stratified according to tumour site (colon or rectum), and Duke’s stage
Participants 325 patients (207 men and 118 women) who had curative resection of newly diagnosed CRC
Exclusions: medical comorbidity making follow up difficult, or 5 year survival unlikely, residence in a
remote area, age >85 years, refusal to participate in the trial, evidence of residual or distant malignancy.
Duke’s A 71
Duke’s B 153
Duke’s C 101
Colon primary 238
Rectal primary 87
Interventions Both groups had regular clinical review, including history, examination and screening investigation at 3,6,
9,12,15,21,24,30,36,42,48,54, 60 months or until a major endpoint was reached. Review was performed
by a nurse research assistant at each visit, and by a consultant surgeon on at least alternate visits.
Clinical signs and symptoms were recorded on a structured ProForma.
Screening investigations at each visit comprised FBC, LFTs, CEA, faecal occult blood testing using the
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Schoemaker 1998 (Continued)
Haemoccult-II test (without hydration) on three faecal samples. All screening or clinical abnormalities
were investigated on merit. Only exception was CEA, an isolated rise in CEA was not used to trigger
further investigations.
In addition patients in the experimental arm underwent yearly CXR, CT liver and colonoscopy.
These investigations were only performed in the control group if indicated on clinical grounds, or after
screening test abnormality, and at 5 years of follow up, to exclude a reservoir of undetected recurrences
Outcomes Overall survival
Notes Setting: Australia
Accrual dates:1984-1990
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Secco 2002
Methods RCT (2 “studies” within 1 publication)
Accrual: 1988-1996
All 358 patients stratified into high and low risk groups
200 classified as high risk
158 classified as low risk
Dropouts from high risk group = 8
Dropouts from low risk group = 13
337 patients randomised - 192 high risk patients into Secco 2002a & 145 low risk patients into Secco
2002b
Single centre trial
Participants 337 patients(163 men, 174 women) who had curative surgery alone for colorectal cancer.
Patients were stratified into High risk (adenoca rectum treated by low ant resection, left colon adenocar-
cinoma modified Duke’s B2 or T3, pre-operative serum CEA greater than or equal to 7.5ng/ml, Duke’s
stage C, poorly differentiated grade, mucinous adenocarcinoma or signet ring cells)
Low risk patients had none of these characteristics
Interventions All patients received education re follow up & the signs and symptoms of possible recurrence. All were
expected to phone the surgical team six monthly.
108 high risk patients were randomised to “intensive follow up” (exp arm) had clinic visits & serum CEA
measured at 3,6,9,12,15,18,21,24,28,32,36,42,48, 54 & 60 months; Abdo/pelvic U/S scans at 6,12,18,
24,30,36,48 & 60 months; CXR 12,24,36,48,60. Patients with rectal ca had rigid sigmoidoscopy &CXR
at 12,24,36,48 & 60 months.
84 high risk patients were randomised to a “minimal follow up programme performed by physicians”
Outcomes Overall survival (actuarial at five years), recurrence, costs, curative re-operations
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Secco 2002 (Continued)
Notes Curative surgery: “macroscopic excision of primary tumour, peritumoural tissues and nodes”
Setting: Italy
Accrual dates:1988-1996
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Wattchow 2006
Methods RCT
Accrual:1998-2001
Multicentered trial
Setting: Australia
Randomisation method: remote and concealed (random numbers)
Single blinded: (researchers)
Baseline characteristics: balanced other than trend to higher education levels in surgeon follow-up group.
Power calculation: power of 80% (two-sided) significant at 0.05, based on primary outcome measures
(quality of life, anxiety and depression and patient satisfaction). Number of patients required was 64, set
target at 100 patients in each arm
Participants 203 patients who had undergone curative surgery for Dukes A, B or C colon cancer who had completed
any post-surgical chemotherapy (rectal cancer excluded because of requirement for sigmoidoscopy in
follow up). Follow up by general practitioners and surgeons had to be available, and informed consent
given.
Patients were randomised at either post-surgical visit or at completion of chemotherapy
Interventions Setting and environment of follow up (primary versus secondary care).
Follow-up guidance, based on current clinical practice and guidance was provided which suggested follow-
up visits as follows:
Three monthly for the first 2 years postoperatively, then 6 monthly for the next 3 years.
Each visit incorporated asking a list of set questions about symptoms, physical examination, annual faecal
occult blood testing and colonoscopy every 3 years
Outcomes Primary: quality of life, depression and anxiety and patient satisfaction.
Other: number and type of investigations, number and time to detection of recurrences, deaths from all
causes at two years
Notes Quality of life based on SF-12 Physical and Mental Health Component scores, at baseline, 12 and 24
months.
Depression and anxiety based on Hospital Anxiety and Depression Scale, measured at baseline, 12 and
24 months.
Patient satisfaction based on Patient Visit-Specific Questionnaire, measured at 24 months
Risk of bias
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Wattchow 2006 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Audisio 2000 Ineligible-not RCT
Bedenne 1999 Ineligible-not RCT
Bruinvels 1994a Ineligible-not RCT
Bruinvels 1995b Ineligible-not RCT
Buyse 1996 Ineligible-not RCT
Eckardt 1994 Ineligible-not RCT
Edelman 1997 Ineligible-not RCT
Gerbes 1994 Ineligible-not RCT
Graber 1998 Ineligible-not RCT
Graham 1998 Ineligible-not RCT
Jorgensen 1993 Ineligible-not RCT
Kjeldsen 1997a Duplicate publication
Kjeldsen 1999 Ineligible-not RCT
Kronborg 1981 Prospective, partly randomised trial, data relating to randomised patients unable to be extracted from paper
Kronborg 1983a Ineligible-not RCT
Kronborg 1988b Duplicate publication
Kronborg 1994c Ineligible-not RCT
Kronborg 2000d Ineligible, not RCT, comment only
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(Continued)
Makela 1992a Early report on included RCT
McCall 1994 Ineligible-not RCT
Padberg 1999 Ineligible-not RCT
Richard 1997 Ineligible-not RCT
Rosen 1998 Ineligible-not RCT
Rotondano 1997 Ineligible-not RCT
Taylor 2000 Ineligible-not RCT
Toouli 1998 Ineligible-not RCT
Characteristics of ongoing studies [ordered by study ID]
COLFOL
Trial name or title A Pragmatic Study to Assess the Frequency of Surveillance Tests After Curative Resection in Patients With
Stage II and III Colorectal Cancer - a Randomised Multicentre Trial
Methods
Participants Radical surgery (R0-resection) for colorectal adenocarcinoma - with or without adjuvant treatment, and
Age < 75 years, and “clean colon” verified by perioperative barium enema or colonoscopy last 3 months post-
surgery, and Tumour stage:II-III (T2, N1-2, M0, T3-4, Nany, M0 ,Dukes´ B - C)
Interventions Low frequency follow up group CEA one month postoperatively
then CEA, CT/ or MRI of the liver and X-ray/CT of the lungs 12 and 36 month after surgery.
High refequency follow up group; CEA one month postoperatively
then CEA, CT or MRI liver and/or PET scans as well as X-ray or CT of the lungs at 6, 12, 18, 24, and 36
months
Outcomes Primary outcomes will be total mortality and cancer-specific mortality at 5 years;
Secondary outcomes will be recurrence-free survival
Starting date
Contact information Peer Wille-Jørgensen, M.D., Dr. Med. Sci.
Department of Surgical Gastroenterology K
H:S - Bispebjerg Hospital
DK-2400 Copenhagen NV
DENMARK
E- Mail: pwj01@bbh.hosp.dk
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COLFOL (Continued)
Notes
FACS
Trial name or title Follow up After Colorectal Surgery (FACS) trial
Methods
Participants All patients who have undergone curative treatment for primary
colorectal cancer (R0 resections, Dukes A-C).
Interventions Group 1: Symptomatic follow up in primary care, with or without a
single CT scan 12-18 months post-randomisation.
Group 2: Tumour marker measurement in primary care (CEA every 3
months for 2 years, then every 6 months for 3 years), with or without a
single CT scan 12-18 months post-randomisation.
Group 3: Intensive hospital follow up with CT (every 6 months for 2
years, then annually for 3 years).
Group 4: Combination of Groups 2&3 (intensive hospital follow up and
primary care-based CEA tumour marker measurement).
Outcomes Primary Objective: Overall survival by intention-to-treat analysis.
Secondary objectives: Quality of life in survivors, Cost of NHS
services utilised, NHS cost per life-year saved.
Starting date March 2004
Contact information Tel: 023 80795155 / 023 80795154
Email: facs@soton.ac.uk
Website: http://www.facs.soton.ac.uk
Notes
GILDA 1998
Trial name or title GILDA : A multicentre randomised trial of intensive versus less intensive follow-up of patients with resected
Duke’s stage B2-C CRC
Methods
Participants Histopathologic diagnosis of adenocarcinoma of the colon or rectum, Dukes Astler-Coller stage B2-C, treated
with curative intent (radical excision +/-adjuvant radio/chemotherapy)
Patient must be free of known cancer prior to entry, attested by normal endoscopy, US, CXR, CEA
Exclusion criteria: Inability to undergo testing (disability, allergy to contrast etc), or geographically not
amenable to follow up. Enrolment in any other protocol requiring specific follow-up practice.
History of any previous malignancy in last 10 years (other than CIS cervix, or non-melanoma skin cancer).
No informed consent.
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GILDA 1998 (Continued)
Interventions Experimental group programme:
4,8,12,16,20,24, 30,36,42,48,60 monthly office visits and history and clinical examination, FBC, CEA and
CA19.9.
Colonoscopy and CXR at
12,24,36,48 and 60 months.
Liver US at 4,8,12,16,24,36, 48 and 60 months.
For rectal patients, pelvic CT at 4,12,24,48 months.
Control group programme: 4,8, 12,16,20,24,30, 42,48,60 monthly office visits, including history, examina-
tion, and CEA.
Colonoscopy at 12 and 48 months.
Liver ultrasound at 4 and 16 months.
Rectal cancer patients in addition have rectoscopy at 4 months, CXR at 12 months, liver US at 8 and
16 months. A single pelvic CT allowed if Radiation Oncologist requires it as baseline following adjuvant
treatment
Outcomes Principal endpoints: overall survival and tumour specific mortality.
Secondary endpoints: quantify lead time due to intensive programme
Treatment of recurrences with curative intent
Sensitivity of follow-up regimens
Compliance with follow-up regimen
Quality of Life HR-QoL self -assessed at baseline, and at 12,24,36,48 and 60 months.
Relapsed patients monitored 2 monthly for one year using EORTC QLQ-30
Starting date 1998
Contact information Fossati R
Mario Negri Institute Milan, Italy
fossati@marionegri.it
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Intensive follow-up versus minimalist follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 6 1601 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.59, 0.91]
2 Recurrence 7 1938 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.75, 1.10]
3 Disease specific survival 2 704 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.64, 1.31]
Comparison 2. Clinic visits and tests versus no clinic visits and tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 107 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.26, 1.29]
2 Recurrence 2 444 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.58, 1.25]
Comparison 3. More clinic visits versus fewer visits
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 2 804 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.58, 1.05]
2 Recurrence 2 804 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.69, 1.26]
Comparison 4. More tests versus fewer tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 5 1004 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.85]
2 Recurrence 5 1004 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.69, 1.16]
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Comparison 5. Community versus hospital
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Recurrence 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 6. CEA versus no CEA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 107 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.26, 1.29]
2 Recurrence 2 444 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.58, 1.25]
Comparison 7. Liver imaging versus no liver imaging
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 5 1004 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.85]
2 Recurrence 6 1341 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.70, 1.10]
Comparison 8. Time to recurrence intensive vs time to recurrence minimalist
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence 3 420 Mean Difference (IV, Random, 95% CI) -6.75 [-11.06, -2.44]
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Comparison 9. Curative surgery attempted at recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Curative surgery at recurrence 6 1613 Odds Ratio (M-H, Fixed, 95% CI) 2.41 [1.63, 3.54]
Analysis 1.1. Comparison 1 Intensive follow-up versus minimalist follow-up, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 1 Intensive follow-up versus minimalist follow-up
Outcome: 1 Mortality
Study or subgroup intensive FU Minimal FU Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 88/290 100/307 34.9 % 0.90 [ 0.64, 1.27 ]
Makela 1995 23/52 27/54 7.6 % 0.79 [ 0.37, 1.70 ]
Ohlsson 1995 15/53 22/54 8.1 % 0.57 [ 0.26, 1.29 ]
Pietra 1998 28/104 43/103 16.3 % 0.51 [ 0.29, 0.92 ]
Rodriguez 2006 21/127 27/132 11.4 % 0.77 [ 0.41, 1.45 ]
Schoemaker 1998 43/167 55/158 21.7 % 0.65 [ 0.40, 1.05 ]
Total (95% CI) 793 808 100.0 % 0.73 [ 0.59, 0.91 ]
Total events: 218 (intensive FU), 274 (Minimal FU)
Heterogeneity: Chi2 = 3.46, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0049)
0.001 0.01 0.1 1 10 100 1000
Favours intensive FU Favours minimal FU
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Analysis 1.2. Comparison 1 Intensive follow-up versus minimalist follow-up, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 1 Intensive follow-up versus minimalist follow-up
Outcome: 2 Recurrence
Study or subgroup Intensive FU Minimalist FU Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 76/290 80/307 25.8 % 1.01 [ 0.70, 1.45 ]
Makela 1995 22/52 21/54 5.4 % 1.15 [ 0.53, 2.50 ]
Ohlsson 1995 17/53 18/54 5.5 % 0.94 [ 0.42, 2.12 ]
Pietra 1998 47/104 53/103 13.2 % 0.78 [ 0.45, 1.34 ]
Rodriguez 2006 35/127 34/132 10.9 % 1.10 [ 0.63, 1.90 ]
Schoemaker 1998 56/167 62/158 19.1 % 0.78 [ 0.50, 1.23 ]
Secco 2002 101/192 83/145 20.2 % 0.83 [ 0.54, 1.28 ]
Total (95% CI) 985 953 100.0 % 0.91 [ 0.75, 1.10 ]
Total events: 354 (Intensive FU), 351 (Minimalist FU)
Heterogeneity: Chi2 = 2.03, df = 6 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
0.001 0.01 0.1 1 10 100 1000
Intensive FU Minimalist FU
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Analysis 1.3. Comparison 1 Intensive follow-up versus minimalist follow-up, Outcome 3 Disease specific
survival.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 1 Intensive follow-up versus minimalist follow-up
Outcome: 3 Disease specific survival
Study or subgroup Intensive followup Minimalist followup Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 61/290 65/307 79.3 % 0.99 [ 0.67, 1.47 ]
Ohlsson 1995 12/53 17/54 20.7 % 0.64 [ 0.27, 1.51 ]
Total (95% CI) 343 361 100.0 % 0.92 [ 0.64, 1.31 ]
Total events: 73 (Intensive followup), 82 (Minimalist followup)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
0.001 0.01 0.1 1 10 100 1000
Favours intensive Favours minimal
Analysis 2.1. Comparison 2 Clinic visits and tests versus no clinic visits and tests, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 2 Clinic visits and tests versus no clinic visits and tests
Outcome: 1 Mortality
Study or subgroup Clinic visits + test No visits or tests Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohlsson 1995 15/53 22/54 100.0 % 0.57 [ 0.26, 1.29 ]
Total (95% CI) 53 54 100.0 % 0.57 [ 0.26, 1.29 ]
Total events: 15 (Clinic visits + test), 22 (No visits or tests)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
0.001 0.01 0.1 1 10 100 1000
Clinic visits + test No visits + tests
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Analysis 2.2. Comparison 2 Clinic visits and tests versus no clinic visits and tests, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 2 Clinic visits and tests versus no clinic visits and tests
Outcome: 2 Recurrence
Study or subgroup Clinic FU + tests No visits + tests Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohlsson 1995 17/53 18/54 21.3 % 0.94 [ 0.42, 2.12 ]
Secco 2002 101/192 83/145 78.7 % 0.83 [ 0.54, 1.28 ]
Total (95% CI) 245 199 100.0 % 0.85 [ 0.58, 1.25 ]
Total events: 118 (Clinic FU + tests), 101 (No visits + tests)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
0.001 0.01 0.1 1 10 100 1000
Clinic FU + tests No clinic FU + tests
Analysis 3.1. Comparison 3 More clinic visits versus fewer visits, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 3 More clinic visits versus fewer visits
Outcome: 1 Mortality
Study or subgroup More visits Less visits Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 88/290 100/307 68.2 % 0.90 [ 0.64, 1.27 ]
Pietra 1998 28/104 43/103 31.8 % 0.51 [ 0.29, 0.92 ]
Total (95% CI) 394 410 100.0 % 0.78 [ 0.58, 1.05 ]
Total events: 116 (More visits), 143 (Less visits)
Heterogeneity: Chi2 = 2.63, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 1.66 (P = 0.098)
0.001 0.01 0.1 1 10 100 1000
More clinic visits Less clinic visits
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Analysis 3.2. Comparison 3 More clinic visits versus fewer visits, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 3 More clinic visits versus fewer visits
Outcome: 2 Recurrence
Study or subgroup More clinic visits Fewer clinic visits Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 76/290 80/307 66.3 % 1.01 [ 0.70, 1.45 ]
Pietra 1998 47/104 53/103 33.7 % 0.78 [ 0.45, 1.34 ]
Total (95% CI) 394 410 100.0 % 0.93 [ 0.69, 1.26 ]
Total events: 123 (More clinic visits), 133 (Fewer clinic visits)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
0.001 0.01 0.1 1 10 100 1000
No clinic FU Clinic FU + tests
Analysis 4.1. Comparison 4 More tests versus fewer tests, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 4 More tests versus fewer tests
Outcome: 1 Mortality
Study or subgroup More tests Tests Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Makela 1995 23/52 27/54 11.7 % 0.79 [ 0.37, 1.70 ]
Ohlsson 1995 15/53 22/54 12.4 % 0.57 [ 0.26, 1.29 ]
Pietra 1998 28/104 43/103 25.1 % 0.51 [ 0.29, 0.92 ]
Rodriguez 2006 21/127 27/132 17.5 % 0.77 [ 0.41, 1.45 ]
Schoemaker 1998 43/167 55/158 33.3 % 0.65 [ 0.40, 1.05 ]
Total (95% CI) 503 501 100.0 % 0.64 [ 0.49, 0.85 ]
Total events: 130 (More tests), 174 (Tests)
Heterogeneity: Chi2 = 1.25, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
0.001 0.01 0.1 1 10 100 1000
More tests Tests
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Analysis 4.2. Comparison 4 More tests versus fewer tests, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 4 More tests versus fewer tests
Outcome: 2 Recurrence
Study or subgroup More tests Tests Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Makela 1995 22/52 21/54 9.9 % 1.15 [ 0.53, 2.50 ]
Ohlsson 1995 17/53 18/54 10.1 % 0.94 [ 0.42, 2.12 ]
Pietra 1998 47/104 53/103 24.4 % 0.78 [ 0.45, 1.34 ]
Rodriguez 2006 35/127 34/132 20.2 % 1.10 [ 0.63, 1.90 ]
Schoemaker 1998 56/167 62/158 35.4 % 0.78 [ 0.50, 1.23 ]
Total (95% CI) 503 501 100.0 % 0.90 [ 0.69, 1.16 ]
Total events: 177 (More tests), 188 (Tests)
Heterogeneity: Chi2 = 1.55, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.42)
0.001 0.01 0.1 1 10 100 1000
No clinic FU Clinic FU + tests
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Analysis 6.1. Comparison 6 CEA versus no CEA, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 6 CEA versus no CEA
Outcome: 1 Mortality
Study or subgroup CEA measured No CEA measured Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohlsson 1995 15/53 22/54 100.0 % 0.57 [ 0.26, 1.29 ]
Total (95% CI) 53 54 100.0 % 0.57 [ 0.26, 1.29 ]
Total events: 15 (CEA measured), 22 (No CEA measured)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
0.001 0.01 0.1 1 10 100 1000
CEA measured No CEA measured
Analysis 6.2. Comparison 6 CEA versus no CEA, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 6 CEA versus no CEA
Outcome: 2 Recurrence
Study or subgroup CEA measured No CEA measured Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohlsson 1995 17/53 18/54 21.3 % 0.94 [ 0.42, 2.12 ]
Secco 2002 101/192 83/145 78.7 % 0.83 [ 0.54, 1.28 ]
Total (95% CI) 245 199 100.0 % 0.85 [ 0.58, 1.25 ]
Total events: 118 (CEA measured), 101 (No CEA measured)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
0.001 0.01 0.1 1 10 100 1000
No clinic FU Clinic FU + tests
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Analysis 7.1. Comparison 7 Liver imaging versus no liver imaging, Outcome 1 Mortality.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 7 Liver imaging versus no liver imaging
Outcome: 1 Mortality
Study or subgroup Liver imaging No liver imaging Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Makela 1995 23/52 27/54 11.7 % 0.79 [ 0.37, 1.70 ]
Ohlsson 1995 15/53 22/54 12.4 % 0.57 [ 0.26, 1.29 ]
Pietra 1998 28/104 43/103 25.1 % 0.51 [ 0.29, 0.92 ]
Rodriguez 2006 21/127 27/132 17.5 % 0.77 [ 0.41, 1.45 ]
Schoemaker 1998 43/167 55/158 33.3 % 0.65 [ 0.40, 1.05 ]
Total (95% CI) 503 501 100.0 % 0.64 [ 0.49, 0.85 ]
Total events: 130 (Liver imaging), 174 (No liver imaging)
Heterogeneity: Chi2 = 1.25, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
0.001 0.01 0.1 1 10 100 1000
Liver imaging No liver imaging
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Analysis 7.2. Comparison 7 Liver imaging versus no liver imaging, Outcome 2 Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 7 Liver imaging versus no liver imaging
Outcome: 2 Recurrence
Study or subgroup Liver imaging No liver imaging Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Makela 1995 22/52 21/54 7.2 % 1.15 [ 0.53, 2.50 ]
Ohlsson 1995 17/53 18/54 7.4 % 0.94 [ 0.42, 2.12 ]
Pietra 1998 47/104 53/103 17.7 % 0.78 [ 0.45, 1.34 ]
Rodriguez 2006 35/127 34/132 14.7 % 1.10 [ 0.63, 1.90 ]
Schoemaker 1998 56/167 62/158 25.7 % 0.78 [ 0.50, 1.23 ]
Secco 2002 101/192 83/145 27.2 % 0.83 [ 0.54, 1.28 ]
Total (95% CI) 695 646 100.0 % 0.88 [ 0.70, 1.10 ]
Total events: 278 (Liver imaging), 271 (No liver imaging)
Heterogeneity: Chi2 = 1.64, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
0.001 0.01 0.1 1 10 100 1000
No clinic FU Clinic FU + tests
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Analysis 8.1. Comparison 8 Time to recurrence intensive vs time to recurrence minimalist, Outcome 1
Recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 8 Time to recurrence intensive vs time to recurrence minimalist
Outcome: 1 Recurrence
Study or subgroup Intensive Minimalist
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Makela 1995 52 10 (8.06) 54 15 (1.31) 37.5 % -5.00 [ -7.22, -2.78 ]
Ohlsson 1995 53 20.4 (20.8) 54 24 (13.68) 20.8 % -3.60 [ -10.28, 3.08 ]
Pietra 1998 104 10.3 (0.43) 103 20.2 (0.69) 41.6 % -9.90 [ -10.06, -9.74 ]
Total (95% CI) 209 211 100.0 % -6.75 [ -11.06, -2.44 ]
Heterogeneity: Tau2 = 11.62; Chi2 = 22.03, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 3.07 (P = 0.0022)
-10 -5 0 5 10
Favours intensive Favours minimlaist
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Analysis 9.1. Comparison 9 Curative surgery attempted at recurrence, Outcome 1 Curative surgery at
recurrence.
Review: Follow-up strategies for patients treated for non-metastatic colorectal cancer
Comparison: 9 Curative surgery attempted at recurrence
Outcome: 1 Curative surgery at recurrence
Study or subgroup Intensive follow up Minimal follow up Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kjeldsen 1997 15/290 5/307 12.9 % 3.29 [ 1.18, 9.18 ]
Makela 1995 5/52 3/54 7.5 % 1.81 [ 0.41, 7.99 ]
Ohlsson 1995 5/53 3/54 7.6 % 1.77 [ 0.40, 7.82 ]
Pietra 1998 21/104 6/103 13.5 % 4.09 [ 1.58, 10.61 ]
Rodriguez 2006 18/127 10/132 23.6 % 2.01 [ 0.89, 4.55 ]
Secco 2002 31/192 13/145 34.9 % 1.96 [ 0.98, 3.89 ]
Total (95% CI) 818 795 100.0 % 2.41 [ 1.63, 3.54 ]
Total events: 95 (Intensive follow up), 40 (Minimal follow up)
Heterogeneity: Chi2 = 2.39, df = 5 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.45 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours minimal FU Favours intensive FU
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